Clinical characteristics at the time of allo-SCT or remission-induction chemotherapy of patients classified according to WHO criteria
| Clinical variables . | Diagnosis, N = 365 . | ||
|---|---|---|---|
| MDS . | AML-MDS . | ||
| No. of patients (%) | 238 (65) | 127 (35) | |
| Median age, y (range) | 48 (17-67) | 47 (23-72) | |
| Sex, no. male/female | 132/106 | 69/58 | |
| WHO classification (%) | |||
| RA/RARS | 27 (7) | — | |
| MDS with del5q31 | 3 (1) | — | |
| RCMD/RS | 57 (16) | — | |
| RAEB-1 | 56 (15) | — | |
| RAEB-2 | 95 (26) | — | |
| WBC, × 109/L (range) | 2.9 (0.2-21.3) | 3.21 (0.1-27.2) | |
| Absolute neutrophil count, | 1.16 (0.01-11.5) | 1.4 (0.2-10.7) | |
| × 109/L (range) | |||
| Hb, g/L (range) | 88 (71-122) | 92 (68-120) | |
| PLT, ×109/L (range) | 48 (3-686) | 58 (3-319) | |
| Cytogenetics (%) | 209/238 (88) | 94/127 (74) | |
| Good | 108 (52) | 49 (52) | |
| Intermediate | 62 (30) | 34 (36) | |
| Poor | 39 (18) | 11 (12) | |
| Transfusion dependency (%) | 115/231 (50) | 73/113 (65) | |
| IPSS risk (%) | 207/238 (87) | — | |
| Low | 5 (2) | — | |
| Intermediate-1 | 90 (43) | — | |
| Intermediate-2 | 95 (46) | — | |
| High | 17 (8) | — | |
| WPSS risk (%) | 181/238 (76) | — | |
| Very low | 3 (2) | — | |
| Low | 18 (10) | — | |
| Intermediate | 33 (18) | — | |
| High | 103 (57) | — | |
| Very high | 24 (13) | — | |
| Clinical variables . | Diagnosis, N = 365 . | ||
|---|---|---|---|
| MDS . | AML-MDS . | ||
| No. of patients (%) | 238 (65) | 127 (35) | |
| Median age, y (range) | 48 (17-67) | 47 (23-72) | |
| Sex, no. male/female | 132/106 | 69/58 | |
| WHO classification (%) | |||
| RA/RARS | 27 (7) | — | |
| MDS with del5q31 | 3 (1) | — | |
| RCMD/RS | 57 (16) | — | |
| RAEB-1 | 56 (15) | — | |
| RAEB-2 | 95 (26) | — | |
| WBC, × 109/L (range) | 2.9 (0.2-21.3) | 3.21 (0.1-27.2) | |
| Absolute neutrophil count, | 1.16 (0.01-11.5) | 1.4 (0.2-10.7) | |
| × 109/L (range) | |||
| Hb, g/L (range) | 88 (71-122) | 92 (68-120) | |
| PLT, ×109/L (range) | 48 (3-686) | 58 (3-319) | |
| Cytogenetics (%) | 209/238 (88) | 94/127 (74) | |
| Good | 108 (52) | 49 (52) | |
| Intermediate | 62 (30) | 34 (36) | |
| Poor | 39 (18) | 11 (12) | |
| Transfusion dependency (%) | 115/231 (50) | 73/113 (65) | |
| IPSS risk (%) | 207/238 (87) | — | |
| Low | 5 (2) | — | |
| Intermediate-1 | 90 (43) | — | |
| Intermediate-2 | 95 (46) | — | |
| High | 17 (8) | — | |
| WPSS risk (%) | 181/238 (76) | — | |
| Very low | 3 (2) | — | |
| Low | 18 (10) | — | |
| Intermediate | 33 (18) | — | |
| High | 103 (57) | — | |
| Very high | 24 (13) | — | |
WBC indicates white blood cell; Hb, hemoglobin; and PLT, platelet.